139757-72-5

Upstream product

• 108-24-7 acetic anhydride 
• 136787-49-0 3-(tert-butyldiphenylsilyloxy)prop-1-ene 
• 137125-19-0 2-[[tert-butyl(diphenyl)silyl]oxymethyl]-1,3-oxathiolan-5-one 
• 125111-27-5 3-((tert-butyldiphenylsilyl)oxy)propane-1,2-diol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 75-36-5 acetyl chloride 
• 145365-08-8 (Z)-2,2,11,11-tetramethyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodec-6-ene 
• 115869-43-7 (tert-butyldiphenylsilanyloxy)acetaldehyde 

Downstream Products

• 136831-90-8 cis-2-<<(tert-butyldiphenylsilyl)oxy>methyl>-5-(cytosin-1'-yl)-1,3-oxathiolane 
• 1022193-74-3 6-amino-3-{2-[(2,2-dimethyl-1,1-diphenyl-1-silapropoxy)methyl]-1,3-oxathiolan-5-yl}-3-hydropyrimidine-2-one 

Relevant academic research and scientific papers

Synthesis of a novel class of 1,3-oxathiolane nucleoside derivatives of T-705 and evaluation of their anti-influenza a virus and anti-HIV activity

Backgroud: T-705 (Favipiravir) is a broad spectrum antiviral agent approved for stockpiling in Japan and currently in Phase 3 testing in the United States. Against influenza, it acts as a prodrug, converted intracellularly to selectively inhibit viral RNA

COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE

An improved process for the manufacture of Lamivudine. The process involves: (a) resolution of racemic lamivudine (intermediate of formula IX) to cis (±) lamivudine of formula (XII) by forming a crystalline salt and separating the product from an organic solvent by fractional crystallization; (b) resolution of cis (±) lamivudine to cis (?) isomer involving formation of S-Binol adduct of formula XIV.

Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives

A series of cyclic and acyclic nucleoside analogues derived from 3-hydroxy-4-pyridinone were synthesized using the Vorbrüggen reaction. Iron chelation studies, and antiviral evaluation against a broad panel of viruses, were performed. The pKa value of ligand 25 and the stability constant of the corresponding iron-(III) complex were compared to those of deferiprone. The pFe3+ values were found to be similar. Some compounds showed moderate activity against both wild-type HSV-1 and HSV-2, as well as against a thymidine kinase deficient strain of HSV-1. These results suggest a novel mode of action for this group of nucleoside analogues.

Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives

We describe the synthesis and the antiviral evaluation of novel α and β dideoxynucleoside derivatives in which the base has been replaced by a 3-hydroxy-2-methylpyridin-4-one. The syntheses were successfully achieved by the use of the standard Vorbrueggen coupling conditions. Moderate activity of these compounds were found on herpes simplex virus (HSV) type 1 and type 2.